Practical guide to a successful digital transition
This guide will go through the basic philosophy of the Pharma 4.0 approach and the practical steps to a successful digital transition.
What is Pharma 4.0?
A special group of pharmaceutical process analysts and engineers has been operating inside the non-profit International Society for Pharmaceutical Engineering. It was named the ISPE Pharma 4.0 Special Interest Group (SIG).
Its goal is to provide a road map for new challenges of digitalization, Industry 4.0, and the smart factory.
It is an operating model that runs from research to product development and all the way to commercial manufacturing. This initiative's ideas were formed from the Industry 4.0 technological advancements, where pharma-specific additions were made at the operational and regulatory level.
They facilitate direct communication between different organization levels and guarantee complete transparency throughout the product lifecycle management circle. Moreover, the connectivity between various information systems, devices, and machines allows for a paperless, data-driven approach, identifying and solving different manufacturing problems.
Interdisciplinary collaboration is now crucial. All SOPs (Standard Operating Procedures) are closely monitored through high-level automation between integrated equipment and processes. This guarantees an enhanced PQS (Pharmaceutical Quality System) and confidence in fact-based decision-making.
Key differences between Pharma 4.0 and traditional pharmaceutical manufacturing
Pharma 4.0 represents a significant shift from traditional pharmaceutical manufacturing by incorporating advanced digital technologies and principles of Industry 4.0. Here are the key differences between Pharma 4.0 and traditional pharmaceutical manufacturing:
Automation vs. manual processes
In traditional pharmaceutical manufacturing, many processes are manual or semi-automated. This includes tasks such as mixing, filling, labeling, and packaging. Operators often perform these tasks based on predefined protocols, with a heavy reliance on human intervention.
Automation is at the core of Pharma 4.0. Advanced robotics, AI-driven systems, and automated machinery handle production processes with minimal human intervention. This automation allows for more consistent and precise operations, reducing the risk of human error and increasing efficiency.
Paper-based documentation vs. digital data management
Documentation in traditional manufacturing is often paper-based, involving physical records of batch production, quality control tests, and compliance reports. This approach is time-consuming, prone to errors, and can lead to delays in product releases.
Pharma 4.0 replaces paper-based documentation with digital data management systems. These systems automatically capture, store, and analyze data in real-time, enabling faster decision-making and more efficient regulatory compliance. Digital records are easier to audit and provide greater transparency.
Reactive quality control vs. predictive quality assurance
Quality control in traditional manufacturing is typically reactive. Products are tested at the end of the production process, and if a batch fails to meet quality standards, it is either reworked or discarded, leading to waste and inefficiencies.
Pharma 4.0 introduces predictive quality assurance through real-time monitoring and data analytics. Sensors and AI systems continuously monitor production parameters, detecting potential issues before they impact product quality. This proactive approach minimizes waste, ensures consistent quality, reduces the likelihood of recalls and improves patient safety.
Isolated systems vs. interconnected systems
Production equipment and systems in traditional manufacturing are often isolated, with limited communication between them. Data is typically siloed, making it difficult to gain a holistic view of the manufacturing process.
Pharma 4.0 leverages the IoT to create interconnected systems where equipment, sensors, and software communicate seamlessly. This integration enables a unified view of the entire production process, allowing for better coordination, optimization, and real-time decision-making.
In summary, Pharma 4.0 marks a paradigm shift from traditional pharmaceutical manufacturing by embracing digital transformation. It offers enhanced efficiency, flexibility, quality, and compliance, positioning the pharmaceutical industry to meet the challenges of modern healthcare, such as the demand for personalized medicine and the need for rapid, responsive production capabilities.
Assessing Pharma 4.0 readiness: tools and techniques
Nevertheless, the biggest hurdle that most of the pharmaceutical companies face before realizing the Pharma 4.0 initiative is the digital maturity level of their organization.
Mechanization, steam power, weaving loom
Mass production, assembly line, electrical energy
Automation, computers and electronics
Cyber physical system, internet of things, network
As we can see in the industrial evolution diagram, different technological advancements led to different corresponding revolutionary changes in the industrial world.
By projecting this categorization on today's pharma manufacturing world, one will find out that most of the companies' infrastructure is at an Industry 3.0 level.
In contrast, others have entire production lines running on Industry 2.0 equipment and processes, using manually produced, paper-based manufacturing records.
The importance of Pharma 4.0: why it matters for the industry
As previously mentioned, Pharma 4.0 is based on Industry 4.0 digital systems and communications.
All the Regulatory requirements must be added, and the process performance systems must be transformed into product quality monitoring systems.
The cloud-based IIoT (Industrial Internet of Things) technologies simultaneously control multiple processes and production plants while collecting more data.
The complete manufacturing environment can be monitored in real-time, configured automatically, and self-corrected through self-learning processes.
For example, by assuming high-level Pharma 4.0 readiness.
Once a packaging line is plugged into a line management system, it should be automatically qualified, validated, and ready to use in a GMP (Good Manufacturing Practices) environment.
Data integrity by design
Failing to do so will lead to a breach of contractual obligations, legal complications, order delays, and an increase in manufacturing costs.
Data is tracked throughout the manufacturing process and is available to ensure high-quality standards.
Realize the ISPE Good Automated Manufacturing Practices (GAMP) Records and Data Integrity Guide (March '17)
Be based on process flowcharts
Provide data in diagrams, following the guidelines of the Global Audit Trail Standards
Track data throughout the expected lifecycle, as instructed by the Regulatory Retention Time
It is continuously collected to provide real-time information that builds deep knowledge around the manufacturing process. It enables the implementation of a predictive control strategy.
Process Performance & Product Quality Monitoring System
Corrective Action / Preventive Action (CAPA) System
Change Management
Management Review
Digital Maturity
Data Integrity by Design
Knowledge Management (KM)
Quality Risk Management (QRM)
Leveraging digitalization and ICH guidelines in Pharma 4.0
The market was flooded with low-quality drugs, as there was no secure way of observing and rewarding quality.
Competition on quality transformed into competition on price.
Increased drug shortages, with quality issues accounting for around 65% of shortages.
This is stated by the International Council for Harmonisation, mainly in the ICH Q10 guideline, concerning PQS.
once a packaging line is plugged into a line management system, it should be automatically qualified, validated, and ready to use in a GMP (Good Manufacturing Practices) environment.
One can observe the connections between the drug commercial manufacturing lifecycle and the previously mentioned PQS elements and enablers.
The role of the holistic control strategy in Pharma 4.0
There was no overarching concept behind the design of these systems, so data could only be used for optimization at a local level. Solving a manufacturing problem meant navigating several systems and connecting the relevant information by hand. Without recorded, detailed and automatically integrated knowledge of the control strategy processes, the data flow and data lifecycle cannot be organized, and the data by design principle cannot be implemented.
What is the holistic control strategy?
A planned set of controls, derived from current product and process understanding, that assures process performance and product quality.
Such a strategy follows a product from research through development, technology transfer and commercial manufacturing. It enables control and holistic lifecycle management, and creates synergy between digital automation and guidelines. It sharpens the quality manufacturing focus, where Quality Target Product Profiles are required for every product. Information from machines and components is available without navigating different systems or searching paper records, and operator comments are logged automatically, which makes continuous improvement easy to implement.
It ensures plug-in compatibility is achieved and paperless data integrity is guaranteed.
Since data integrity and automatic validation sit at the core of Pharma 4.0, the diagram below sets out the data and process flows involved.
Pharma 4.0 summary: key takeaways for industry leaders
From the above discussion, it should be clear that Pharma 4.0 is a strategic choice for leveraging emerging digital technologies.
The gains from the shift in mentality and the requested investments can be summarized in the following points:
Knowledge management and Quality Risk Management are at the heart of a continuously monitored manufacturing process
Risk levels are decreased, quality levels are increased, and time to market is reduced
Interconnectivity and silos breaking allows for better management of complex supply chain issues
Streamlined digital workflows can save time and money wasted on ineffective production loops, poor communication, and delayed decision making
Manufacturing costs reduction, due to minimized deviation from drug recipes, order schedules, and other contractual obligations
Artificial intelligence (AI) driven decisions guarantee a higher level of GMP application
Machine Learning (ML) functionalities allow for predictive analytics, bottlenecks removal, and smarter maintenance
The close manufacturing process monitoring will reduce insecurity and everyday stress
Elimination of paper-based records will make better use of the workers' time
A higher level of engagement can drive innovative thinking
Recorded personal performance data can be used for more effective people management
Given all these multi-level benefits, the shift to a Pharma 4.0 operating model should be a straightforward decision for a life sciences company.
However, many things need to change (from people's mentality to infrastructure and processes) to reach the highest manufacturing performance levels and quality. In the following paragraphs, we will explain and give you examples of how you can safely make this transition.
